2015 ACR/ARHP Annual Meeting

November 6-11, 2015. San Francisco, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2944

Presepsin (sCD14 subtype) Concentration Is Elevated and Reflects Disease Activity in Systemic Lupus Erythematous Patients
Abstract Number: 511

Pretreatment Prediction of Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptors in Individual Rheumatoid Arthritis Patient
Abstract Number: 1219

Prevalence and Clinical Characteristics of Rheumatoid Arthritis in Poland: First Nationwide Study
Abstract Number: 1004

Prevalence and Cross-Sectional Risk Factors of Ankle Osteoarthritis in a Community-Based Cohort
Abstract Number: 1706

Prevalence and Factors Associated with Non-Traumatic Vertebral Fractures in Psoriatic Arthritis
Abstract Number: 2265

Prevalence and Physical and Mental Health Patterns of Rheumatic and Musculoskeletal Diseases in Portugal: Results from a National Health Survey
Abstract Number: 43

Prevalence and Relevance of Depressive Symptoms in Patients with Rheumatic Diseases
Abstract Number: 1877

Prevalence and Risk Factors for Left Ventricular Diastolic Dysfunction in Scleroderma
Abstract Number: 1820

Prevalence and Risk-Factors for Asymptomatic Coronary-Artery Calcifications in Young Patients with Systemic Lupus Erythematosus
Abstract Number: 1395

Prevalence and Significance of MEFV GENE Mutations in Patients with Sarcoidosis
Abstract Number: 2264

Prevalence and Social Burden of Active Chronic Low Back Pain in the Adult Portuguese Population – Results from a National Survey
Abstract Number: 372

Prevalence of Atypical Fractures in a Tertiary Hospital
Abstract Number: 226

Prevalence of Cardiovascular Disease in Patients with Gout, Osteoarthritis or Both
Abstract Number: 3162

Prevalence of Chronic Comorbidities in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis and Systemic Lupus Erythematosus: An Analysis of UK Biobank Data
Abstract Number: 1549

Prevalence of Co-Morbidities and Evaluation of Their Monitoring in Korean Patients with RA: Comparison with the Results of an International, Cross-Sectional Study (COMORA)

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].